H1 2020 Insomnia Pipeline Review - ResearchAndMarkets.com

The "Insomnia - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Insomnia (Central Nervous System) pipeline landscape.

Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Insomnia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 12, 6, 1, 7 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Insomnia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Insomnia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Insomnia (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Insomnia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Insomnia (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Insomnia - Overview
• Insomnia - Therapeutics Development
• Insomnia - Therapeutics Assessment
• Insomnia - Companies Involved in Therapeutics Development
• Insomnia - Drug Profiles
• Insomnia - Dormant Projects
• Insomnia - Discontinued Products
• Insomnia - Product Development Milestones
• Appendix

Companies Mentioned

• Amherst Pharmaceuticals LLC
• Artelo Biosciences Inc
• Biohemp International Inc
• Cannabis Science Inc
• Cennerv Pharma (S) Pte Ltd
• Ci Therapeutics
• Druggability Technologies Holdings Ltd
• Eisai Co Ltd
• EUSOL Biotech Co Ltd
• Evotec SE
• Grupo Ferrer Internacional SA
• Guangdong East Sunshine Pharmaceutical Co Ltd
• Idorsia Pharmaceutical Ltd
• Imbrium Therapeutics LP
• Intra-Cellular Therapies Inc
• Jazz Pharmaceuticals Plc
• Johnson & Johnson
• Linnet BioPharmaceuticals Inc
• M et P Pharma AG
• NB Health Laboratory Co Ltd
• Neurim Pharmaceuticals Ltd
• NeuroFix Therapeutics LLC
• Overseas Pharmaceuticals Ltd
• Renascence Therapeutics Ltd
• Reviva Pharmaceuticals Inc
• Sage Therapeutics Inc
• Shionogi & Co Ltd
• Taisho Pharmaceutical Holdings Co Ltd
• Tetranov International Inc
• Tritech Biopharmaceuticals Co Ltd
• Yangtze River Pharmaceutical Group
• Zelira Therapeutics Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/za1u6y

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005562/en/